Literature DB >> 7512375

Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein.

E Sadovnikova1, X Zhu, S M Collins, J Zhou, K Vousden, L Crawford, P Beverley, H J Stauss.   

Abstract

Human papilloma virus (HPV) type 16 is found in the majority of cervical cancer patients and the transforming protein E7 is consistently expressed in cancer cells, making it a potential target for immune attack. In this study we have investigated whether E7 gains access to the MHC class I processing pathway and provides cytotoxic T lymphocyte (CTL) stimulating peptide epitopes. CTL were induced in H-2b mice by immunization with recombinant vaccinia virus expressing E7 (Vac-E7). To map CTL recognition, natural peptides were purified from cells expressing either intact or truncated E7 protein. Following peptide separation by HPLC one major CTL epitope was detected and truncated constructs localized this epitope to the C-terminal region. Mapping with synthetic peptides indicated that residues 49-57 (RAHYNIVTF) were recognised by anti-E7 CTL. Synthetic 49-57 peptide was used to induce CTL, which recognized the same HPLC purified natural peptide fractions as anti-E7 CTL. Binding motifs for H-2b class I molecules did not predict residues 49-57 to be a CTL epitope, but instead the sequence 21-28 (DLYCYEQL) which contains a Kb anchor motif. Synthetic 21-28 peptide was found to bind to Kb class I molecules and readily induced CTL, indicating that the T cell repertoire of H-2b mice can recognize this epitope. However, these CTL did not recognize peptides isolated from E7 expressing cells, showing that natural processing did not produce detectable levels of the 21-28 epitope. Together, the data demonstrate that an unexpected E7 peptide can function as a major CTL epitope.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7512375     DOI: 10.1093/intimm/6.2.289

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  15 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

2.  Ex Vivo PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients.

Authors:  Yuan Chen; Shao-An Xue; Shahriar Behboudi; Goran H Mohammad; Stephen P Pereira; Emma C Morris
Journal:  Clin Cancer Res       Date:  2017-07-14       Impact factor: 12.531

3.  Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6.

Authors:  G B Lipford; S Bauer; H Wagner; K Heeg
Journal:  Immunology       Date:  1995-02       Impact factor: 7.397

4.  Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity.

Authors:  W Shi; P Bu; J Liu; A Polack; S Fisher; L Qiao
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

5.  Steric recognition of T-cell receptor contact residues is required to map mutant epitopes by immunoinformatical programmes.

Authors:  Shiou-Chih Hsu; Chih-Peng Chang; Chao-Yuan Tsai; Shih-Hung Hsieh; Betty A Wu-Hsieh; Yu-Shu Lo; Jinn-Moon Yang
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

6.  HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein.

Authors:  Mayumi Nakagawa; Kevin H Kim; Tiffany M Gillam; Anna-Barbara Moscicki
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

Review 7.  TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers.

Authors:  Kelly Barrios; Esteban Celis
Journal:  Cancer Immunol Immunother       Date:  2012-04-22       Impact factor: 6.968

8.  Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy.

Authors:  E Sadovnikova; H J Stauss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

9.  Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice.

Authors:  Yi-Fang Chen; Chih-Wei Lin; Yeou-Ping Tsao; Show-Li Chen
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

10.  Specificity of the H-2 L(d)-restricted cytotoxic T-lymphocyte response to the mouse hepatitis virus nucleocapsid protein.

Authors:  C C Bergmann; S A Stohlman
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.